查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933320

細胞療法市場規模、佔有率、成長及全球產業分析：依類型、應用、區域洞察及預測（2026-2034 年）

Cell Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 210 Pages | 商品交期: 請詢問到貨日

價格

細胞療法市場成長驅動因子

受技術進步、先進細胞療法的日益普及以及針對腫瘤和罕見疾病治療需求不斷增長的推動，全球細胞療法市場正經歷快速增長。預計該市場規模將在 2025 年達到 88.8 億美元，2026 年達到 123.4 億美元，到 2034 年達到 1903.6 億美元，預測期內複合年增長率 (CAGR) 高達 40.78%。

細胞療法是一種治療方法，將自體或來自其他捐贈者的活細胞輸注給患者，以治療或預防疾病。 這包括源自基因工程改造的T細胞、自然殺手細胞和誘導多能幹細胞（iPS細胞）的療法，這些療法能夠恢復正常細胞功能、清除病變細胞並再生受損組織。該市場由諾華公司、吉利德科學公司和百時美施貴寶公司等大型生物製藥公司引領，並受益於強大的研發管線、豐富的產品線和全球佈局。

市場動態

市場驅動因素

龐大的未滿足醫療需求，尤其是在腫瘤學和罕見遺傳疾病領域，是推動市場發展的關鍵因素。許多罕見疾病（約佔所有疾病的95%）缺乏FDA核准的治療方法，因此對個人化細胞療法的需求日益增長。鐮狀細胞疾病患者數量的不斷增長（據估計，2021年全球患者人數為774萬人）進一步推動了對標靶療法的需求。 CAR-T 和基因修飾 T 細胞療法的快速臨床進展和不斷擴大的批准正在推動市場成長。

市場限制因子

安全問題和臨床風險，例如腫瘤形成、免疫排斥、移植物抗宿主疾病 (GVHD)、細胞激素釋放症候群 (CRS) 和神經毒性，限制了市場擴張。這些風險需要專門的醫院基礎設施，並將實施限制在經過認證的機構。例如，Yescarta（吉利德科學公司）在約 32% 的大 B 細胞淋巴瘤患者中出現了 3 級或更高等級的神經毒性。

市場機會

異基因細胞療法的出現提供了即用型解決方案，實現了規模化、降低成本並加快了治療啟動。技術進步和對腫瘤學、自體免疫疾病和神經系統疾病應用領域投資的增加，帶來了巨大的成長機會。 例如，2025年6月，Allogene Therapeutics公佈了ALLO-316治療晚期腎細胞癌的I期臨床試驗的良好數據。

市場挑戰

高昂的治療費用仍然是一項重大挑戰。 CAR-T療法，例如Yescarta，每個療程的費用約為537,592美元，此外還有住院和治療後護理費用。這限制了患者獲得治療的機會，尤其是在醫療預算有限的新興市場。

市場趨勢

一個顯著的趨勢是細胞療法的應用範圍從血液系統惡性腫瘤擴展到實體腫瘤。各公司正在開發雙重和三重CAR-T細胞療法，以克服抗原逃脫並提高實體瘤的療效。 2024年2月，Iovance Biotherapeutics的AMTAGVI（lifileucel）獲得FDA批准用於治療晚期黑色素瘤，顯示監管機構對腫瘤領域的創新療法給予了支持。

市場區隔分析

依療法分類：

  • CAR-T 細胞療法將保持其主導地位，到 2026 年將佔 98.78% 的市場佔有率，這主要得益於監管部門的批准、市場接受度的提高以及對臨床研發管線的投資。
  • 其他療法包括 TCR-T 細胞療法和自然殺手 (NK) 細胞療法。

依產品分類：

  • Yescarta 憑藉其龐大的患者群體、優惠的報銷體係以及遍布全球的 570 多家授權治療中心，在市場上佔領先地位。
  • Abecma 預計在預測期內將以 14.66% 的複合年增長率成長。

依適應症劃分：

  • 在大量已批准的產品、不斷擴大的臨床試驗和投資的推動下，腫瘤領域將在2025年佔100%的市場佔有率。
  • 其他適應症的市佔率有限，預計到2032年將達到1,000萬美元。

依最終使用者劃分：

  • 由於擁有專業的醫療基礎設施和完善的醫保報銷機制，醫院和診所將繼續保持領先地位，預計到2026年將佔55.43%的市場佔有率。
  • 專科診所預計將以42.11%的複合年增長率成長。

區域展望

  • 北美：最大的市場，2025 年市場規模為 42.2 億美元，2026 年為 58.8 億美元。這主要得益於已上市產品、強大的臨床研發管線以及阿斯特捷利康 2025 年在美國研發和生產設施方面投資 5,000 萬美元。美國將成為最大的貢獻者，2026 年市場規模將達到 54.8 億美元。
  • 歐洲：2025 年市場規模將達到 23.9 億美元，年複合成長率 (CAGR) 為 36.55%。 2026年，英國和德國分別貢獻了5.3億美元和7.9億美元。 亞太地區：預計2025年市場規模將達到14.5億美元，其中日本（4.3億美元）、中國（7.7億美元）和印度（1.3億美元）將是2026年的主要市場。 拉丁美洲：預計2025年市場規模將達4.8億美元，但由於基礎建設限制，普及率有限。 中東和非洲：預計2025年海灣合作委員會（GCC）市場規模將達1.9億美元，成長速度放緩。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 概述：細胞療法在新疾病適應症的進展
  • 主要國家的監管環境
  • 市場技術進步
  • 主要公司的新產品發布
  • 主要公司的研發管線分析
  • 主要產業趨勢（併購、合作、新產品發表）等等）
  • 市場格局中的定價與報銷趨勢
  • 製造與供應鏈洞察
  • 市場投資與融資趨勢

第五章：全球細胞療法市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測 - 依療法分類
    • CAR-T 細胞療法
    • TCR-T 細胞療法
    • 自然殺手 (NK) 細胞療法
    • 其他療法
  • 市場分析、洞察與預測 - 依產品分類
    • Kymriah
    • Yescata
    • Tecartas
    • Bryanji
    • Abekuma
    • Kalvikti
    • 其他療法
  • 市場分析、洞察與預測 - 依適應症
    • 腫瘤科
    • 其他
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 醫院和診所
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美細胞治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲細胞治療市場分析、洞察與預測2021-2034

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章 亞太細胞治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲細胞治療市場分析、洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲細胞療法市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章：競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol Myers Squibb Company
  • Johnson &Johnson
  • Vertex Pharmaceuticals Incorporated
  • Bayer AG
  • Adaptimmune
  • IOVANCE Biotherapeutics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics
Product Code: FBI114224

Growth Factors of cell therapy Market

The global cell therapy market is experiencing rapid growth, driven by technological advancements, increasing adoption of advanced cellular therapies, and rising demand for treatments targeting oncology and rare diseases. The market was valued at USD 8.88 billion in 2025, projected to grow to USD 12.34 billion in 2026, and is expected to reach USD 190.36 billion by 2034, reflecting a robust CAGR of 40.78% during the forecast period.

Cell therapy involves the administration of live cells, either autologous or allogeneic, into patients to treat or prevent diseases. These therapies include genetically engineered T-cells, natural killer cells, and induced pluripotent stem cell (iPSC)-derived therapies that restore normal cellular function, eliminate diseased cells, or regenerate damaged tissues. The market is dominated by leading biopharmaceutical players including Novartis AG, Gilead Sciences, Inc., and Bristol Myers Squibb, supported by strong R&D pipelines, wide product availability, and global reach.

Market Dynamics

Market Drivers

High unmet medical needs, particularly in oncology and rare genetic diseases, are a major driver. Many rare diseases, comprising approximately 95% of conditions, lack FDA-approved treatments, creating demand for personalized cell therapies. The increasing number of patients with conditions such as sickle cell disease, estimated at 7.74 million globally in 2021, further fuels the need for targeted therapies. Rapid clinical progress in CAR-T and engineered T-cell therapies, coupled with expanding approvals, is propelling market growth.

Market Restraints

Safety concerns and clinical risks, including tumorigenesis, immune rejection, graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and neurotoxicity, restrict market expansion. These risks necessitate specialized hospital infrastructure and limit adoption to certified centers. For instance, Yescarta (Gilead Sciences, Inc.) recorded grade >=3 neurotoxicity in ~32% of patients with large B-cell lymphoma.

Market Opportunities

The emergence of allogeneic cell therapies offers off-the-shelf solutions, providing scalability, lower costs, and faster treatment initiation. Technological advancements and growing investment in oncology, autoimmune, and neurological applications provide significant growth opportunities. For example, Allogene Therapeutics reported promising Phase 1 data for ALLO-316 in June 2025, targeting advanced renal cell carcinoma.

Market Challenges

The high cost of treatment remains a significant challenge. CAR-T therapies such as Yescarta cost around USD 537,592 per regimen, with additional costs for hospitalization and post-treatment care. This limits accessibility, especially in emerging economies with constrained healthcare budgets.

Market Trends

A notable trend is the expansion of cell therapy applications beyond hematology into solid tumors. Companies are developing dual- and tri-CAR T-cells to overcome antigen escape and improve efficacy in solid cancers. In February 2024, the FDA approved AMTAGVI (lifileucel) by Iovance Biotherapeutics for advanced melanoma, demonstrating regulatory support for innovative therapies in oncology.

Segmentation Analysis

By Therapy Type:

  • CAR-T cell therapy dominates with 98.78% market share in 2026, driven by regulatory approvals, market adoption, and investment in clinical pipelines.
  • Other therapy types include TCR-T and natural killer (NK) cell therapies.

By Product:

  • Yescarta leads the market due to a large target patient base, favorable reimbursement, and global distribution through over 570 authorized treatment centers.
  • Abecma is projected to grow at 14.66% CAGR during the forecast period.

By Indication:

  • Oncology dominates with 100% market share in 2025, fueled by a high number of approved products, expanding clinical trials, and investment flow.
  • Other indications are limited, projected at USD 0.01 billion by 2032.

By End-User:

  • Hospitals & clinics dominate, holding 55.43% market share in 2026, due to specialized infrastructure and alignment with reimbursement frameworks.
  • Specialty clinics are projected to grow at 42.11% CAGR.

Regional Outlook

  • North America: Dominates with USD 4.22 billion in 2025 and USD 5.88 billion in 2026, driven by commercialized products, strong clinical pipelines, and investments such as USD 50 million by AstraZeneca in U.S. R&D and manufacturing facilities in 2025. The U.S. is the largest contributor with USD 5.48 billion in 2026.
  • Europe: Valued at USD 2.39 billion in 2025, growing at 36.55% CAGR, with the UK and Germany contributing USD 0.53 billion and USD 0.79 billion respectively in 2026.
  • Asia Pacific: Estimated at USD 1.45 billion in 2025, with key markets including Japan (USD 0.43 billion), China (USD 0.77 billion), and India (USD 0.13 billion) in 2026.
  • Latin America: Valued at USD 0.48 billion in 2025, adoption limited due to infrastructure constraints.
  • Middle East & Africa: GCC valued at USD 0.19 billion in 2025, showing slower growth.

Competitive Landscape

The market is semi-fragmented, with major players such as Novartis AG, Gilead Sciences, Bristol Myers Squibb, Johnson & Johnson, Iovance Biotherapeutics, Fate Therapeutics, and Adaptimmune. Strategies include R&D, collaborations, licensing, and clinical partnerships to strengthen market presence.

Key Developments:

  • June 2025: EMA recommended conditional marketing authorization for Zemcelpro in the EU.
  • June 2025: BMS received U.S. FDA approval for Abecma and Breyanzi CAR-T therapies.
  • April 2025: Thermo Fisher launched the Advanced Therapies Collaboration Center in California.
  • August 2024: FDA approved the first TCR therapy, afami-cel, for synovial sarcoma.
  • April 2024: India launched NexCAR19, its first homegrown CAR-T therapy.

Conclusion

The global cell therapy market is expected to grow from USD 8.88 billion in 2025 to USD 190.36 billion by 2034, at a CAGR of 40.78%. Growth is driven by the increasing adoption of CAR-T and allogeneic therapies, rising unmet medical needs in oncology and rare diseases, expanding regulatory approvals, and strategic investments by key market players. Despite high treatment costs and safety concerns, cell therapy is poised to revolutionize personalized medicine, offering curative solutions and improving patient outcomes globally.

Segmentation By Therapy Type

  • CAR-T Cell Therapy
  • TCR-T Cell Therapy
  • Natural Killer (NK) Cells
  • Others

By Product

  • Kymriah
  • Yescarta
  • Tecartus
  • Breyanzi
  • Abecma
  • Carvykti
  • Others

By Indication

  • Oncology
  • Others

By End User

  • Hospitals & Clinics
  • Specialty Clinics
  • Others

By Geography

  • North America (By Therapy Type, Product, Indication, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Advancements in of Cell Therapy for New Disease Indications
  • 4.2. Regulatory Scenarios, By Key Countries/Regions
  • 4.3. Technological Advancements in the Market
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Companies
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
  • 4.7. Pricing & Reimbursement Landscape in the Market
  • 4.8. Manufacturing & Supply Chain Insights
  • 4.9. Investment & Funding Trends in the Market

5. Global Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.1.1. CAR-T Cell Therapy
    • 5.1.2. TCR-T Cell Therapy
    • 5.1.3. Natural Killer (NK) Cells
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. Kymriah
    • 5.2.2. Yescarta
    • 5.2.3. Tecartus
    • 5.2.4. Breyanzi
    • 5.2.5. Abecma
    • 5.2.6. Carvykti
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Oncology
    • 5.3.2. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.1.1. CAR-T Cell Therapy
    • 6.1.2. TCR-T Cell Therapy
    • 6.1.3. Natural Killer (NK) Cells
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. Kymriah
    • 6.2.2. Yescarta
    • 6.2.3. Tecartus
    • 6.2.4. Breyanzi
    • 6.2.5. Abecma
    • 6.2.6. Carvykti
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Oncology
    • 6.3.2. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.1.1. CAR-T Cell Therapy
    • 7.1.2. TCR-T Cell Therapy
    • 7.1.3. Natural Killer (NK) Cells
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. Kymriah
    • 7.2.2. Yescarta
    • 7.2.3. Tecartus
    • 7.2.4. Breyanzi
    • 7.2.5. Abecma
    • 7.2.6. Carvykti
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Oncology
    • 7.3.2. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.1.1. CAR-T Cell Therapy
    • 8.1.2. TCR-T Cell Therapy
    • 8.1.3. Natural Killer (NK) Cells
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. Kymriah
    • 8.2.2. Yescarta
    • 8.2.3. Tecartus
    • 8.2.4. Breyanzi
    • 8.2.5. Abecma
    • 8.2.6. Carvykti
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Oncology
    • 8.3.2. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.1.1. CAR-T Cell Therapy
    • 9.1.2. TCR-T Cell Therapy
    • 9.1.3. Natural Killer (NK) Cells
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. Kymriah
    • 9.2.2. Yescarta
    • 9.2.3. Tecartus
    • 9.2.4. Breyanzi
    • 9.2.5. Abecma
    • 9.2.6. Carvykti
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Oncology
    • 9.3.2. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.1.1. CAR-T Cell Therapy
    • 10.1.2. TCR-T Cell Therapy
    • 10.1.3. Natural Killer (NK) Cells
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. Kymriah
    • 10.2.2. Yescarta
    • 10.2.3. Tecartus
    • 10.2.4. Breyanzi
    • 10.2.5. Abecma
    • 10.2.6. Carvykti
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Oncology
    • 10.3.2. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Specialty Clinics
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Novartis AG
    • 11.2.2. Gilead Sciences, Inc.
    • 11.2.3. Bristol Myers Squibb Company
    • 11.2.4. Johnson & Johnson
    • 11.2.5. Vertex Pharmaceuticals Incorporated
    • 11.2.6. Bayer AG
    • 11.2.7. Adaptimmune
    • 11.2.8. IOVANCE Biotherapeutics, Inc.
    • 11.2.9. F. Hoffmann-La Roche Ltd
    • 11.2.10. Fate Therapeutics

List of Tables

  • Table 1: Global Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 2: Global Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 3: Global Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 4: Global Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 5: Global Cell Therapy Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 7: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 8: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 9: North America Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 10: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 12: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 13: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 14: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 15: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 17: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 18: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 19: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 20: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 22: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 23: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 24: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 25: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 27: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 28: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 29: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 30: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cell Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cell Therapy Market Value Share (%), By Therapy Type, 2025 & 2034
  • Figure 3: Global Cell Therapy Market Value Share (%), By Product, 2025 & 2034
  • Figure 4: Global Cell Therapy Market Value Share (%), By Indication, 2025 & 2034
  • Figure 5: Global Cell Therapy Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global Cell Therapy Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 7: North America Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 8: North America Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 9: North America Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 10: North America Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 11: North America Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 12: North America Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 13: North America Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 14: North America Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 15: North America Cell Therapy Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 16: North America Cell Therapy Market Value Share (%), By Country, 2025
  • Figure 17: Europe Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 18: Europe Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 19: Europe Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 20: Europe Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 21: Europe Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 22: Europe Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 23: Europe Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 24: Europe Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 25: Europe Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 28: Asia Pacific Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 29: Asia Pacific Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 30: Asia Pacific Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 31: Asia Pacific Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 33: Asia Pacific Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 34: Asia Pacific Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 38: Latin America Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 39: Latin America Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 40: Latin America Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 41: Latin America Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 42: Latin America Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 43: Latin America Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 44: Latin America Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 45: Latin America Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 49: Middle East & Africa Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 50: Middle East & Africa Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 51: Middle East & Africa Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 53: Middle East & Africa Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cell Therapy Market Share (%), By Company, 2025